Loading
NASDAQHealthcareBiotechnology
Latest quote
$0.8011
−$0.0137 · -1.68%
Akebia Therapeutics, Inc., established in 2007 and headquartered in Cambridge, Massachusetts, is a biopharmaceutical company focused on discovering and commercializing therapies for patients suffering from kidney diseases. The firm's leading experimental drug, vadadustat, is an oral treatment currently in Phase III clinical trials. Its purpose is to address anemia resulting from chronic kidney disease (CKD) in adult patients, encompassing both those dependent on dialysis and those who are not. Akebia also markets Auryxia, a ferric citrate product used to manage serum phosphorus levels in adult CKD patients undergoing dialysis, and to treat iron deficiency anemia in adult CKD patients who are not on dialysis. The company has several key collaboration agreements: with Otsuka Pharmaceutical Co. Ltd. for vadadustat's development and commercialization across major regions including the United States, European Union, Russia, China, Australia, Canada, and the Middle East; with Mitsubishi Tanabe Pharma Corporation for vadadustat in Japan and other Asian territories; and a research and licensing deal with Janssen Pharmaceutica NV pertaining to hypoxia-inducible factor prolyl hydroxylase targeted compounds globally.
Latest quote
$0.8011
−$0.0137 · -1.68%
After-hours
$0.8165
+$0.0154 · +1.92%
Oct 9, 5:02 PM ET
Regular session · ET · Market data may be delayed.
Akebia Therapeutics, Inc., established in 2007 and headquartered in Cambridge, Massachusetts, is a biopharmaceutical company focused on discovering and commercializing therapies for patients suffering from kidney diseases. The firm's leading experimental drug, vadadustat, is an oral treatment currently in Phase III clinical trials. Its purpose is to address anemia resulting from chronic kidney disease (CKD) in adult patients, encompassing both those dependent on dialysis and those who are not. Akebia also markets Auryxia, a ferric citrate product used to manage serum phosphorus levels in adult CKD patients undergoing dialysis, and to treat iron deficiency anemia in adult CKD patients who are not on dialysis. The company has several key collaboration agreements: with Otsuka Pharmaceutical Co. Ltd. for vadadustat's development and commercialization across major regions including the United States, European Union, Russia, China, Australia, Canada, and the Middle East; with Mitsubishi Tanabe Pharma Corporation for vadadustat in Japan and other Asian territories; and a research and licensing deal with Janssen Pharmaceutica NV pertaining to hypoxia-inducible factor prolyl hydroxylase targeted compounds globally.
Day range
Current $0.8011
52-week range
Current $0.8011
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
82
Deep Value
Sentiment
49
Mixed
Risk
63
High Risk
Momentum
45
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Akebia Therapeutics, Inc., established in 2007 and headquartered in Cambridge, Massachusetts, is a biopharmaceutical company focused on discovering and commercializing therapies for patients suffering from kidney diseases. The firm's leading experimental drug, vadadustat, is an oral treatment currently in Phase III clinical trials. Its purpose is to address anemia resulting from chronic kidney disease (CKD) in adult patients, encompassing both those dependent on dialysis and those who are not. Akebia also markets Auryxia, a ferric citrate product used to manage serum phosphorus levels in adult CKD patients undergoing dialysis, and to treat iron deficiency anemia in adult CKD patients who are not on dialysis. The company has several key collaboration agreements: with Otsuka Pharmaceutical Co. Ltd. for vadadustat's development and commercialization across major regions including the United States, European Union, Russia, China, Australia, Canada, and the Middle East; with Mitsubishi Tanabe Pharma Corporation for vadadustat in Japan and other Asian territories; and a research and licensing deal with Janssen Pharmaceutica NV pertaining to hypoxia-inducible factor prolyl hydroxylase targeted compounds globally.
Day range
Current $0.8011
52-week range
Current $0.8011
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 236.2M USD | 160.18M USD | 194.62M USD | 292.48M USD | 211.65M USD |
| Cost of goods sold | 39.46M USD | 63.18M USD | 74.15M USD | 22.5M USD | 81.49M USD |
| Gross profit | 196.73M USD | 97M USD | 120.47M USD | 269.99M USD | 130.16M USD |
| Research and development | 62.36M USD | 37.65M USD | 63.08M USD | 165.99M USD | 147.85M USD |
| Selling, general, and administrative | 107.48M USD | 106.55M USD | 100.23M USD | 138.6M USD | 174.14M USD |
| Operating expenses | 173.24M USD | 147.48M USD | 166.73M USD | 350.77M USD | 394.66M USD |
| Interest expense | 24.18M USD | 18.19M USD | 6.03M USD | 15.69M USD | 19.94M USD |
| Depreciation and amortization | 1.27M USD | 37.5M USD | 37.63M USD | 37.7M USD | 37.97M USD |
| Operating income | 23.5M USD | −50.47M USD | −46.26M USD | −80.78M USD | −264.5M USD |
| Net income | −5.35M USD | −69.41M USD | −51.93M USD | −94.23M USD | −282.02M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$1.00
24.83% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI7.27M0.00%2.3T USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM5.66M0.01%77.7B USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF2.84M0.00%95.4B USD0.05%$235+0.80%
Fidelity Enhanced Small Cap ETFFESM1.72M0.03%6.41B USD0.28%$45.46+0.46%
iShares Russell 2000 Growth ETFIWO1.64M0.01%14.04B USD0.24%$356.78+0.94%
Vanguard Russell 2000 ETFVTWO1.36M0.01%18B USD0.06%$112.66+0.50%
Schwab U.S. Small-Cap ETFSCHA1.26M0.01%21.73B USD0.03%$32.79+0.40%
Vanguard Health Care ETFVHT701.69K0.00%22B USD0.09%$319.01+1.64%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFFidelity Enhanced Small Cap ETFFESMiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAVanguard Health Care ETFVHTAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
